Safe vectors for gene therapy

Details Safe vectors for gene therapy Safe vectors for gene therapy

1995-06-06

1998-04-21

Elliott, George C.

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

424 932, A61K 4800

Patent

active

057414866

ABSTRACT:
The present invention provides retroviral vectors comprising direct repeats flanking a sequence that is desired to be deleted upon reverse transcription in a host cell. In a preferred embodiment the sequence that is desired to be deleted is the retroviral cis-acting encapsidation sequence (E) essential for virus production in helper cells. In gene therapy embodiments, the E sequence is deleted upon reverse transcription in target cells, thus preventing spread of retroviral vectors to non-target cells in the event of infection with replication competent viruses. The retroviral vectors of the present invention thus provide safe vectors for gene therapy.

REFERENCES:
patent: 4861719 (1989-08-01), Miller
patent: 4866042 (1989-09-01), Neuwelt
patent: 4980289 (1990-12-01), Temin et al.
patent: 5082670 (1992-01-01), Gage et al.
patent: 5219740 (1993-06-01), Miller et al.
patent: 5240846 (1993-08-01), Collins et al.
patent: 5278056 (1994-01-01), Bank et al.
patent: 5399346 (1995-03-01), Anderson et al.
Boris-Lawrie et al. (1993) "Recent Advances in Retrovirus Vector Technology", Current Opinion in Genetics and Development 3, 102-109.
Pathak et al. (1990) "Broad Spectrum of in vivo Forward Mutations, Hypermutations and Mutational Hotspots in a Retroviral Shuttle Vector after a Single Replication Cycle: Substitutions, Frameshifts and Hypermutations", Proc. Natl. Acad. Sci. USA 87, 6019-6023.
Pathak et al. (1990) "Broad Spectrum of in vivo Forward Mutations, Hypermutations and Mutational Hotspots in a Retroviral Shuttle Vector after a Single Replication Cycle: Deletions and Deletions with Insertions", Proc. Natl. Acad. Sci. USA 87, 6024-6028.
Watt et al. (1993) "A Review of Gene Transfer Techniques", The American Journal of Surgery 165, 350-354.
Jones et. al (1994) "One Retroviral RNA is Sufficient for Synthesis of viral DNA" J. Virol. 68:207-216.
Yan et al. (1994) "A double hairpin structure is necessary for the efficient encapsidation of spleen necrosis virus retroviral DNA" Embo J. 13:713-726.
Marshall, Science, 269:1050-1055, 1995.
Miller et al., FASE B J., 9:190-199, 1995.
Culver et al., TIG, 10(5): 174-178, 1994.
Hodgson., Exp. Opin. Ther. Pat., 5(5):459-468, 1995.
Julias et al., J. Virology, 69(11): 6839-6846, 1995.
Yu et al., Proc. Nat. Acad. Sci., 83:3194-3198, 1986.
Rhode et al., J, Virology, 61(3):,925-927, 1987.
Flamant et al., J. Gen. Virology, 74:39-46, 1993.

Affiliated with

Also associated with

Rating

Safe vectors for gene therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Safe vectors for gene therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Safe vectors for gene therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2055277